Status: Recruiting
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
This pivotal phase 2/3, multi-center, adaptive design study of L-Annamycin for Injection in combination with Cytarabine Injection as second line therapy for remission induction in adult subjects with refractory/relapsed AML is divided into two parts, Part A and Part B.
Participants needed: 312
Trial details
Phase: Phase 2, Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: Moleculin Biotech, Inc.Updated: Jun 17, 2026Locations: 25
Eligibility criteria
Has a pathologically confirmed diagnosis of AML per the 2022 International Conse... [+13]
Has prior or current diagnosis of acute promyelocytic leukemia (APL) or myelodys... [+21]